Skip to content
lsd.com
CompletedPhase 1

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

NCT01046630 · AstraZeneca

Closed to entry
Status
Not accepting participants
Phase 1
Phase
128
Target enrolment
2
Study sites
Outside the US

What it is testing

Summary

The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in depressed subjects.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Measurements of BOLD signal in the brain area BA25

    Measured over Day1 (at infusion)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 45 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * Documented clinical diagnosis meeting criteria from the DSM-IV by structured clinical interview,major depressive disorder, single episode or recurrent * Outpatient status at screening and at randomisation Exclusion Criteria: * A major depression disorder which has a major impact on the subjects current psychiatric status * Subjects not allowed to use mood stabilizers, antidepressants or other antipsychotic or psychoactive drugs * Subjects with lifetime history of schizophrenia, bi-polar, psychosis and psychotic depression

Where

2 study sites

FacilityCityRegionCountry
Research SiteManchester—United Kingdom
Research SiteOxford—United Kingdom

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT01046630 on ClinicalTrials.gov →

Last updated in the registry 2014-10-13. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Indication